Published online before print January 3, 2006, doi: 10.1161/CIRCULATIONAHA.105.581405
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:286-295.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling
From Medical Clinic II/V, University Hospital, Giessen, Germany (R.D., N.W., H.A.G., E.D., W.S., F.G., R.T.S.); Pharma Research Center, Bayer HealthCare, Wuppertal, Germany (J.S., M.J.G.); Rudolf Buchheim Institute for Pharmacology, Giessen, Germany (K.B., H.S.); and Department of Pharmacology, Monash University, Victoria, Australia (H.S.).
Correspondence to Ralph Theo Schermuly, PhD, Zentrum für Innere Medizin, Justus-Liebig Universität Giessen, Klinikstrasse 36, 35392 Giessen, Germany. E-mail ralph.schermuly{at}innere.med.uni-giessen.de
Received August 6, 2005; revision received October 17, 2005; accepted October 31, 2005.
Background— Severe pulmonary hypertension is a disabling disease with high mortality, characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild-type and homozygous endothelial nitric oxide synthase (NOS3–/–) knockout mice with pulmonary hypertension induced by chronic hypoxia and rats with monocrotaline-induced pulmonary hypertension, we examined whether the soluble guanylate cyclase (sGC) stimulator Bay41-2272 or the sGC activator Bay58-2667 could reverse pulmonary vascular remodeling.
Methods and Results— Both Bay41-2272 and Bay58-2667 dose-dependently inhibited the pressor response of acute hypoxia in the isolated perfused lung system. When wild-type (NOS3+/+) or NOS3–/– mice were housed under 10% oxygen conditions for 21 or 35 days, both strains developed pulmonary hypertension, right heart hypertrophy, and pulmonary vascular remodeling, demonstrated by an increase in fully muscularized peripheral pulmonary arteries. Treatment of wild-type mice with the activator of sGC, Bay58-2667 (10 mg/kg per day), or the stimulator of sGC, Bay41-2272 (10 mg/kg per day), after full establishment of pulmonary hypertension from day 21 to day 35 significantly reduced pulmonary hypertension, right ventricular hypertrophy, and structural remodeling of the lung vasculature. In contrast, only minor efficacy of chronic sGC activator therapies was noted in NOS3–/– mice. In monocrotaline-injected rats with established severe pulmonary hypertension, both compounds significantly reversed hemodynamic and structural changes.
Conclusions— Activation of sGC reverses hemodynamic and structural changes associated with monocrotaline- and chronic hypoxia-induced experimental pulmonary hypertension. This effect is partially dependent on endogenous nitric oxide generated by NOS3.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., September 2, 2008; 1(35): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xue, C. A. Ducsay, L. D. Longo, and L. Zhang Effect of long-term high-altitude hypoxia on fetal pulmonary vascular contractility J Appl Physiol, June 1, 2008; 104(6): 1786 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., March 4, 2008; 1200(1): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., March 4, 2008; 1(9): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirsch, B. Kemp-Harper, N. Weissmann, F. Grimminger, and H. H. H. W. Schmidt Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling FASEB J, January 1, 2008; 22(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Leblais, E. Delannoy, F. Fresquet, H. Begueret, N. Bellance, S. Banquet, C. Allieres, L. Leroux, C. Desgranges, A. Gadeau, et al. {beta}-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent {beta}2 component in pulmonary hypertension Cardiovasc Res, January 1, 2008; 77(1): 202 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. V. Evgenov, D. S. Kohane, K. D. Bloch, J.-P. Stasch, G. P. Volpato, E. Bellas, N. V. Evgenov, E. S. Buys, M. J. Gnoth, A. R. Graveline, et al. Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1138 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vermeersch, E. Buys, P. Pokreisz, G. Marsboom, F. Ichinose, P. Sips, M. Pellens, H. Gillijns, M. Swinnen, A. Graveline, et al. Soluble Guanylate Cyclase-{alpha}1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia Circulation, August 21, 2007; 116(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zakrzewicz, M. Hecker, L. M. Marsh, G. Kwapiszewska, B. Nejman, L. Long, W. Seeger, R. T. Schermuly, N. W. Morrell, R. E. Morty, et al. Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension Circulation, June 12, 2007; 115(23): 2957 - 2968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Frutos, R. Spangler, D. Alo, and L. V. G. Bosc NFATc3 Mediates Chronic Hypoxia-induced Pulmonary Arterial Remodeling with {alpha}-Actin Up-regulation J. Biol. Chem., May 18, 2007; 282(20): 15081 - 15089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Morty, B. Nejman, G. Kwapiszewska, M. Hecker, A. Zakrzewicz, F. M. Kouri, D. M. Peters, R. Dumitrascu, W. Seeger, P. Knaus, et al. Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1072 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boerrigter, L. C. Costello-Boerrigter, A. Cataliotti, H. Lapp, J.-P. Stasch, and J. C. Burnett Jr Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure Hypertension, May 1, 2007; 49(5): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, N. Weissmann, H. A. Ghofrani, C. Kaulen, T. Dunkern, C. Schudt, et al. Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy Circulation, May 1, 2007; 115(17): 2331 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Franco and S. Oparil Is There a New Treatment for Hypertensive Disease in the Horizon?: Role of Soluble Guanylate Cyclase Hypertension, November 1, 2006; 48(5): 822 - 823. [Full Text] [PDF]
|
|